

Long-acting, reversible contraception device inventory and separate inpatient reimbursement

Summary: Statewide Medicaid Managed Care Managed Medical Assistance members will soon have the benefit of immediate postpartum placement of long-acting, reversible contraception (LARC) (intrauterine devices and etonogestrel implants) during their inpatient delivery admission.

What is the impact of this change?

Beginning October 25, 2017, payment for LARC devices and professional insertion fees will be paid separately from inpatient admissions. Facilities and providers will receive the same reimbursement as if the device was implanted on an outpatient basis.

To help ensure LARC devices are accessible to physicians and immediately available to patients who request this procedure, hospitals are encouraged to stock OB units with the following:

LARC devices
Intrauterine copper contraceptive, ten-year duration (ParaGard®)
Levonorgestrel-releasing intrauterine contraceptive system, 13.5 mg, three-year duration (Skyla®)
Etonogestrel (contraceptive) implant system including implant and supplies, three-year duration (Nexplanon®)
Levonorgestrel-releasing intrauterine contraceptive system, 52 mg, three-year duration (Liletta®)
Levonorgestrel-releasing intrauterine contraceptive system, 52 mg, five-year duration (Mirena®)
Levonorgestrel-releasing intrauterine system, 19.5 mg, five-year duration (Kyleena®)

We appreciate your assistance in providing reliable contraceptive options for your patients — our members. We look forward to working with you to ensure the success of this program.

What if I need assistance?

For more information or if you have questions about this communication, received it in error or need help with any other item, contact your local Provider Relations representative or call Provider Services at 1-800-454-3730.